AVBP Latest Headlines

Analysts Offer Insights on Healthcare Companies: Xenon (XENE), ArriVent BioPharma, Inc. (AVBP) and PepGen Inc. (PEPG)

at www.tipranks.com (Tue, 10-Nov 11:01 AM)

ArriVent BioPharma, Inc. (AVBP) Gets a Buy from Oppenheimer

at www.tipranks.com (Tue, 10-Nov 7:55 AM)

Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Cormedix (CRMD) and Hims & Hers Health (HIMS)

at www.tipranks.com (Tue, 10-Nov 7:40 AM)

Buy Rating Reiterated as ALPACCA Progress and Pipeline Catalysts Support Unchanged $29 Price Target

at www.tipranks.com (Tue, 10-Nov 6:36 AM)

ArriVent BioPharma GAAP EPS of -$0.81

at seekingalpha.com (Tue, 10-Nov 5:26 AM)

ArriVent Reports Third-Quarter Results and Oncology Pipeline Progress

at www.tipranks.com (Mon, 9-Nov 5:24 PM)

ArriVent to spotlight late-breaking Phase 1 ARR-217 data at ESMO 2026, with an October 26 webinar slated

Market Chameleon (Mon, 26-Oct 11:01 AM)

AVBP Rises After Cancer Cell Publication Highlights Firmonertinib’s Response and PFS in EGFR PACC-Mutant NSCLC

Market Chameleon (Mon, 19-Oct 11:57 AM)

AVBP Shares React After FURVENT Misses Primary PFS Endpoint Despite Higher Confirmed Response Rate at 240 mg

Market Chameleon (Tue, 6-Oct 9:03 AM)